Cargando…
Concomitant BET and MAPK blockade for effective treatment of ovarian cancer
Ovarian cancer is the most lethal gynecologic malignancy, and it is imperative to develop new treatments to ameliorate patient survival. Using an anti-cancer drug library containing 180 small molecule inhibitors, we performed a high-content image-based screen and found that BET and MEK inhibitors ar...
Autores principales: | Jing, Ying, Zhang, Zhenfeng, Ma, Pengfei, An, Shimin, Shen, Ying, Zhu, Liang, Zhuang, Guanglei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823054/ https://www.ncbi.nlm.nih.gov/pubmed/26575423 http://dx.doi.org/10.18632/oncotarget.6309 |
Ejemplares similares
-
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
por: Zhang, Zhenfeng, et al.
Publicado: (2016) -
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
por: Ma, Pengfei, et al.
Publicado: (2016) -
Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer
por: Zhang, Shengzhe, et al.
Publicado: (2015) -
BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022) -
Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)